Videos
Leukemia
Tanios Bekaii-Saab, MD, discusses the results from the phase III BEACON CRC study; investigators evaluated the efficacy and safety of triplet encorafenib, binimetinib, and cetuximab in patients with BRAF V600E–mutant metastatic colorectal cancer who previously received up to 2 lines of prior therapy.
Chronic Myeloid Leukemia
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
2
Allostatic Load Emerges as a Risk Marker for Early-Onset Cancer
3
FDA Approves Expanded Automated PD-L1 Diagnostic Testing Across 4 Solid Tumor Types
4
Velzatinib Aims For Future Direct Comparison With Imatinib in GIST
5